Industry Eagerly Awaits Details Of New Therapeutic Discovery Tax Credit

The euphoria the biotech industry first felt when a federal tax credit that could help recover R&D costs was signed into law has been replaced by curiosity about what will be required in applications for the credit and how applicants might be prioritized